Halloween adcomm postponed as FDA seeks more Ipsen data on ultra rare disorder drug candidate
In a new setback for Paris-based Ipsen, the FDA is postponing an adcomm meeting that was set for Oct. 31 to review new information on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
